Altered centrosomes in ataxia-telangiectasia cells and rapamycin-treated Chinese hamster cells. 2005

Stefania Bonatti, and Marcella Simili, and Pier Alberto Benedetti, and Fabio Morandi, and Paola Menichini, and Renata Del Carratore, and Roberto Barale, and Angelo Abbondandolo
CNR Institute of Clinical Physiology, Pisa, Italy.

Rapamycin induces chromosome malsegregation in mammalian cell lines and yeast. Previous studies indicate that the function impaired in ataxia-telangiectasia (A-T) patients is necessary for both the growth inhibition and the chromosome malsegregation induced by rapamycin, and that treating the non-tumorigenic Chinese hamster cell line CHEF/18 with rapamycin results in supernumerary centrosomes and multipolar spindles. In this paper we report that lymphoblastoid cell lines established from A-T patients as well as hamster A-T-like cells are more resistant to rapamycin than the respective normal cell lines. Two cell lines derived from Nijmegen Breakage Syndrome (NBS) patients, who have clinical symptoms similar to those of A-T but a different molecular defect, were not resistant to rapamycin. Both A-T lymphoblastoid cells and A-T-like fibroblasts had giant centrosomes formed by more than two areas of gamma-tubulin-reacting material. Such giant centrosomes were also observed in CHEF/18 cells after prolonged treatment with rapamycin. Formation of giant centrosomes, possibly due to the coalescence of supernumerary centrosomes, was associated with increased aneuploidy in treated cells. Expression analysis of cell-cycle regulatory genes in rapamycin-treated human lymphoblastoid cells indicated that rapamycin decreased the expression of the tumor suppressor gene GADD45. The levels of RB, p21 and p53 mRNA were also decreased, although to a lesser extent. As rapamycin is often used as an immunosuppressant in pediatric transplant patients, these data indicate that caution should be taken, especially when the drug is given for prolonged periods of time.

UI MeSH Term Description Entries
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008677 Metaphase The phase of cell nucleus division following PROMETAPHASE, in which the CHROMOSOMES line up across the equatorial plane of the SPINDLE APPARATUS prior to separation.
D008941 Spindle Apparatus A microtubule structure that forms during CELL DIVISION. It consists of two SPINDLE POLES, and sets of MICROTUBULES that may include the astral microtubules, the polar microtubules, and the kinetochore microtubules. Mitotic Apparatus,Mitotic Spindle Apparatus,Spindle Apparatus, Mitotic,Meiotic Spindle,Meiotic Spindle Apparatus,Mitotic Spindle,Apparatus, Meiotic Spindle,Apparatus, Mitotic,Apparatus, Mitotic Spindle,Apparatus, Spindle,Meiotic Spindles,Mitotic Spindles,Spindle Apparatus, Meiotic,Spindle, Meiotic,Spindle, Mitotic,Spindles, Meiotic,Spindles, Mitotic
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D002875 Chromosomes In a prokaryotic cell or in the nucleus of a eukaryotic cell, a structure consisting of or containing DNA which carries the genetic information essential to the cell. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Chromosome
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug

Related Publications

Stefania Bonatti, and Marcella Simili, and Pier Alberto Benedetti, and Fabio Morandi, and Paola Menichini, and Renata Del Carratore, and Roberto Barale, and Angelo Abbondandolo
October 1993, Mutation research,
Stefania Bonatti, and Marcella Simili, and Pier Alberto Benedetti, and Fabio Morandi, and Paola Menichini, and Renata Del Carratore, and Roberto Barale, and Angelo Abbondandolo
September 1996, Oncogene,
Stefania Bonatti, and Marcella Simili, and Pier Alberto Benedetti, and Fabio Morandi, and Paola Menichini, and Renata Del Carratore, and Roberto Barale, and Angelo Abbondandolo
January 1985, Kroc Foundation series,
Stefania Bonatti, and Marcella Simili, and Pier Alberto Benedetti, and Fabio Morandi, and Paola Menichini, and Renata Del Carratore, and Roberto Barale, and Angelo Abbondandolo
April 1978, Experimental cell research,
Stefania Bonatti, and Marcella Simili, and Pier Alberto Benedetti, and Fabio Morandi, and Paola Menichini, and Renata Del Carratore, and Roberto Barale, and Angelo Abbondandolo
February 2000, International journal of radiation biology,
Stefania Bonatti, and Marcella Simili, and Pier Alberto Benedetti, and Fabio Morandi, and Paola Menichini, and Renata Del Carratore, and Roberto Barale, and Angelo Abbondandolo
December 1994, International journal of radiation biology,
Stefania Bonatti, and Marcella Simili, and Pier Alberto Benedetti, and Fabio Morandi, and Paola Menichini, and Renata Del Carratore, and Roberto Barale, and Angelo Abbondandolo
January 2013, The Journal of biological chemistry,
Stefania Bonatti, and Marcella Simili, and Pier Alberto Benedetti, and Fabio Morandi, and Paola Menichini, and Renata Del Carratore, and Roberto Barale, and Angelo Abbondandolo
March 1983, Biochemistry,
Stefania Bonatti, and Marcella Simili, and Pier Alberto Benedetti, and Fabio Morandi, and Paola Menichini, and Renata Del Carratore, and Roberto Barale, and Angelo Abbondandolo
August 1978, Cancer research,
Stefania Bonatti, and Marcella Simili, and Pier Alberto Benedetti, and Fabio Morandi, and Paola Menichini, and Renata Del Carratore, and Roberto Barale, and Angelo Abbondandolo
February 1989, Mutation research,
Copied contents to your clipboard!